CGEM
Cullinan Therapeutics, Inc.
Key Financials
Operating Income
$-241648000
↓ 22.7%
Net Income
$-219879000
↓ 31.4%
Revenue
$0
↓ 100.0%
Total Assets
$448.4M
↓ 27.9%
EPS (Diluted)
$-3.69
↓ 255.0%
Shareholders' Equity
$408.7M
↓ 30.8%
Total Liabilities
$39.6M
↑ 25.9%
Cash & Equivalents
$88.3M
↑ 6.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/16/2026 | View on SEC |
| 8-K | 6/10/2026 | View on SEC |
| 8-K | 6/8/2026 | View on SEC |
| 8-K | 5/18/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| 144 | 5/5/2026 | View on SEC |
| S-3ASR | 4/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CGEM |
| Company Name | Cullinan Therapeutics, Inc. |
| CIK | 1789972 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-410-4650 |